Immunotherapy plus chemo and radiation shows promise for bulky lung cancer
NCT ID NCT05888402
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy and radiation can help people with large, locally advanced non-small cell lung cancer. About 50 participants will receive two cycles of toripalimab plus chemo, followed by chemoradiation and then up to a year of toripalimab. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Toripalimab (an immunotherapy drug) plus chemotherapy and radiation therapy
- What this could lead to
- If successful, this combination could improve how long people with bulky lung cancer live without their disease getting worse.
- What could go wrong
- This is a small, early-phase trial (50 people) with no control group, so results may not be definitive. Immunotherapy can cause serious immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCAL ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China